Isocitrate dehydrogenase mutations as potential tumour agnostic targets

Read full text Summarise with VIRAT
Authors: Teresa Mercade Macarulla, Ghazaleh Tabatabai, Silvia Stacchiotti, John A. Bridgewater
Cited by: 0
References: 82

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The isocitrate dehydrogenase (IDH) family of proteins comprises three important metabolic enzymes that convert isocitrate to alpha ketoglutarate (α-KG) via oxidative decarboxylation. The IDH enzymes play important roles in epigenetic regulation, DNA repair, and cellular metabolism and biosynthesis. In mutant IDH (m IDH ) cells, α-KG is converted into the functional oncometabolite 2-hydroxyglutarate (2-HG) in a process that consumes the reduced form of nicotinamide adenine dinucleotide phosphate to generate its oxidised form. 2-HG competitively inhibits α-KG from binding to the active site of histone and DNA demethylases, leading to hypermethylation, which inhibits cellular differentiation and induces tumour cell proliferation. Increased 2-HG also has other effects on cellular biology, including altered metabolism, dysregulation of gene expression, alterations in the DNA damage repair pathway, inflammation, and cell death, therefore supporting and promoting tumorigenesis. m IDH genes are associated with a variety of cancers, including but not limited to, cholangiocarcinoma, acute myeloid leukaemia, glioma, and chondrosarcoma, and the incidences of m IDH in these cancers varies and is approximately 13%, 33%, 73%, and 56%, respectively. The biological effects of m IDH are distinct in different cancers, but the reason that m IDH promotes tumour development in some tissues and not others is not clear. m IDH has no definitive prognostic impact in these cancers, except glioma, in which it is a disease-defining marker due to its distinct prognostic significance. m IDH1 /2 are actionable mutations that represent therapeutic targets, however available targeted therapies to treat m IDH cancers are lacking. This article discusses m IDH genes and their importance in each of these cancers. • Isocitrate dehydrogenase mutations are targetable alterations in several cancers. • Frequency and impact of isocitrate dehydrogenase mutations vary between cancers. • Early molecular testing allows the appropriate treatment option to be determined.

Fields of Study & Subjects

Cancer Hypoxia and Metabolism Glioma Diagnosis and Treatment Chromatin Remodeling and Cancer

Publication details

Journal / source
European Journal of Cancer Supplements
Volume
17
Pages
1–10
Publication date
1 March 2026
Language
EN